Summary: Neuromod Devices has appointed Tom Maher as general counsel, bringing his extensive legal and business experience in the life sciences industry to support the company’s global expansion of its Lenire tinnitus treatment device.


  1. Tom Maher joins Neuromod Devices with over 25 years of experience in the life sciences sector, including roles in corporate counsel and operations, enhancing the company’s leadership as it advances its strategic initiatives.
  2. As general counsel, Maher will oversee Neuromod’s legal, governance, and compliance functions, crucial as the company scales its operations and navigates complex international markets.
  3. Maher’s appointment aligns with Neuromod’s ongoing efforts to broaden the global reach of Lenire, following recent expansions in the U.S. and Europe, emphasizing the company’s commitment to redefining tinnitus care worldwide.

Neuromod Device, a medical technology business that created the Lenire tinnitus treatment device, announced the appointment of Tom Maher as general counsel, effective July 5, 2024.

Maher most recently served as chief of operations, corporate counsel, and company secretary for Amarin Pharmaceuticals Ireland, and has a successful track record in three C-Suite positions for publicly traded companies.

“I am pleased to announce the appointment of Tom as Neuromod Devices’ General Counsel. Tom’s extensive background in international business and corporate operations in the life sciences industry will be an invaluable asset to Neuromod Devices as we continue to redefine tinnitus care on a global scale.” says Ross O’Neil, PhD, Neuromod Devices founding CEO.

A life Sciences Industry Veteran

Maher joins Neuromod Devices Ltd. with more than twenty-five years of corporate legal and business experience in the international life sciences industry, including biopharma, biotech, and medtech.

In the role of general counsel, Maher will be responsible for legal and contractual affairs, corporate transactions, governance, and corporate compliance for Neuromod.

“I am excited to join the Neuromod leadership team as the company advances the commercialization of Lenire,” Maher says. “I look forward to working with Ross and the broader team to drive the execution of Neuromod’s ambitious strategic plans in 2024 and beyond.”

Maher’s appointment comes as Neuromod continues to expand the global availability of Lenire. Earlier this year, the organization increased the number of hearing and tinnitus care practices it partners with in the United States of America to more than 80. Neuromod also increased the availability of Lenire in Europe by establishing partnerships with additional practices in Spain, Italy, and the Principality of Monaco.

Photo: Neuromod